| Literature DB >> 26248224 |
Ruimei Sun1, Jinde Wang2, Xiaojiang Li1, Lei Li1, Jie Yang1, Yanxin Ren1, Yan Xi1, Chuanzheng Sun1.
Abstract
BACKGROUND: Iodine intake is related to thyroid disease. This study investigated the effect of the amount of iodine intake on p14ARF and p16INK4a expression of thyroid papillary carcinoma in rats.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26248224 PMCID: PMC4532191 DOI: 10.12659/MSM.893486
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Figure 1Thyroid tissue morphology observation. (A) Normal thyroid tissue, SP×200; (B) Thyroid tissue in group LI, SP×100; (C) Thyroid tissue in group NI, SP×100; (D) Thyroid tissue in group HI, SP×200.
Figure 2p14ARF and p16INK4a expression. (A) p14ARF expression in the control, SP×100; (B) p16INK4a expression in the control, SP×100; (C) p14ARF expression in group LI, SP×100; (D) p16INK4a expression in group LI, SP×100; (E) p14ARF expression in group NI, SP×100; (F) p16INK4a expression in group NI, SP×100; (G) p14ARF expression in group HI, SP×100; (H) p16INK4a expression in group HI, SP×100.
p14ARF and p16INK4a expression positive rate comparison [n(%)].
| Group | Cases | p14ARF | p16INK4a | ||
|---|---|---|---|---|---|
| Positive | Negative | Positive | Negative | ||
| Group LI | |||||
| 6 weeks | 30 | 11 (36.67) | 19 (63.33) | 13 (43.33) | 17 (56.67) |
| 12 weeks | 30 | 3 (10.00) | 27 (90.00) | 5 (16.67) | 25 (83.33) |
| Group NI | |||||
| 6 weeks | 30 | 14 (46.67) | 16 (53.33) | 16 (53.33) | 14 (46.67) |
| 12 weeks | 30 | 10 (33.33) | 20 (66.67) | 13 (43.33) | 17 (56.67) |
| Group HI | |||||
| 6 weeks | 30 | 10 (33.33) | 20 (66.67) | 12 (40.00) | 18 (60.00) |
| 12 weeks | 30 | 2 (6.67) | 28 (93.33) | 3 (10.00) | 27 (90.00) |
| Control | |||||
| 6 weeks | 30 | 24 (80.00) | 6 (20.00) | 27 (90.00) | 3 (10.00) |
| 12 weeks | 30 | 26 (86.67) | 4 (13.33) | 28 (93.33) | 2 (6.67) |
Compared with control, P<0.05;
compared with group NI, P<0.05;
compared with 6 weeks, P<0.05.
Serum thyroid hormone levels and urine iodine level comparison (χ̄±s).
| Group | Cases | FT3 (ng/ml) | FT4 (ng/ml) | TSH (uIU/ml) | Urine iodine (μg/L) |
|---|---|---|---|---|---|
| Group LI | |||||
| 6 weeks | 30 | 2.41±0.54 | 0.83±0.29 | 3.59±1.01 | 33.14±1.26 |
| 12 weeks | 30 | 2.29±0.49 | 0.74±0.21 | 3.71±1.13 | 34.51±1.39 |
| Group NI | |||||
| 6 weeks | 30 | 2.81±0.78 | 1.01±0.36 | 3.04±0.97 | 85.17±4.22 |
| 12 weeks | 30 | 2.79±0.74 | 0.99±0.34 | 3.06±0.92 | 84.46±4.53 |
| Group HI | |||||
| 6 weeks | 30 | 2.19±0.36 | 0.69±0.21 | 3.81±0.94 | 2470.02±106.12 |
| 12 weeks | 30 | 2.05±0.27 | 0.62±0.16 | 3.92±1.03 | 2490.26±112.07 |
| Control | |||||
| 6 weeks | 30 | 3.46±0.82 | 1.33±0.17 | 2.05±0.57 | 84.21±4.63 |
| 12 weeks | 30 | 3.49±0.87 | 1.32±0.15 | 2.07±0.48 | 85.22±4.57 |
Compared with control, P
compared with group NI, P<0.05;
compared with 6 weeks, P<0.05.
Thyroid tumor weight changes comparison (χ̄±s, mg).
| Group | Cases | Thyroid tumor weight |
|---|---|---|
| Group LI | ||
| 6 weeks | 30 | 2.01±0.24 |
| 12 weeks | 30 | 4.19±0.52 |
| Group NI | ||
| 6 weeks | 30 | 1.97±0.21 |
| 12 weeks | 30 | 2.32±0.34 |
| Group HI | ||
| 6 weeks | 30 | 2.03±0.35 |
| 12 weeks | 30 | 4.27±0.49 |
Compared with 6 weeks, P<0.05;
compared with group NI, P<0.05.